Centinel Spine® Completed Enrollment in First-of-its-Kind 2-Level IDE Trial Evaluating prodisc® C Match-the-Disc™ Cervical TDR System
On June 13, 2023, Centinel Spine®, LLC, a leading global medical device company addressing cervical and lumbar spinal disease by providing the most robust and clinically-proven total disc replacement technology platform in the world, announced the completion of enrollment in a first-of-its-kind Investigational Device Exemption (IDE) study which aims to evaluate the safety and effectiveness of the prodisc C Vivo and prodisc C SK cervical total disc replacement (TDR) system.
The trial which enrolled 431 subjects at 29 sites t...